Last Updated: November 8, 2026

Details for New Drug Application (NDA): 021992

NDA 021992 describes PRISTIQ, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the PRISTIQ profile page.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for 021992

Tradename:	PRISTIQ
Applicant:	Pf Prism Cv
Ingredient:	desvenlafaxine succinate
Patents:	1

Pharmacology for NDA: 021992

Mechanism of Action	Cytochrome P450 2D6 Inhibitors Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for 021992

Antidepressive Agents
Serotonin and Noradrenaline Reuptake Inhibitors

Suppliers and Packaging for NDA: 021992

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1210	0008-1210-30	30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1210-30)
PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1211	0008-1211-01	90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 50MG BASE
Approval Date:	Feb 29, 2008	TE:	AB	RLD:	Yes
Patent:	8,269,040	Patent Expiration:	Jul 5, 2027	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 100MG BASE
Approval Date:	Feb 29, 2008	TE:	AB	RLD:	Yes
Patent:	8,269,040	Patent Expiration:	Jul 5, 2027	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 25MG BASE
Approval Date:	Aug 20, 2014	TE:	AB	RLD:	Yes
Patent:	8,269,040	Patent Expiration:	Jul 5, 2027	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 021992

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	6,673,838	⤷ Start Trial
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	6,673,838	⤷ Start Trial
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	7,291,347	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.